Evidence map›Paper›PMID 24129701›Full record

ArticleScience signaling2013

Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses.

Matthew L Wheeler, Matthew B Dong, Robert Brink, Xiao-Ping Zhong, Anthony L DeFranco

Abstract read
In one paragraph

Article in Science signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Diacylglycerol kinase is a keystone regulator of signaling relevant to the pathophysiology of asthma.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  3. Article
  4. Article
  5. Aberrant B-Cell Activation in Systemic Lupus Erythematosus.Kidney diseases (Basel, Switzerland) · 2022
    Review
  6. Review
  7. FCRL1 Regulates B Cell Receptor-Induced ERK Activation through GRB2.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. DGK α and ζ Activities Control TFrontiers in immunology · 2019
    Article
  13. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.The New England journal of medicine · 2018
    Article
  14. Developmental expression of B cell molecules in equine lymphoid tissues.Veterinary immunology and immunopathology · 2017
    Article
  15. Review
  16. Diacylglycerol Kinases in T Cell Tolerance and Effector Function.Frontiers in cell and developmental biology · 2016
    Review
  17. The Immunomodulatory Functions of Diacylglycerol Kinase ζ.Frontiers in cell and developmental biology · 2016
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Matthew L Wheeler1Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Matthew B Dong
Robert Brink
Xiao-Ping Zhong
Anthony L DeFranco
University of California, San Francisco · USDuke University Hospital · USGarvan Institute of Medical Research · AU

Funding

Regulation of peripheral T cell toleranceR01AI079088 · NIAID · DUKE UNIVERSITY · PI ZHONG, XIAOPING · 2008 to 2019
$3.5M
REGULATION OF B-LYMPHOCYTE PROLIFERATION BY ANTIGENR01AI020038 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEFRANCO, ANTHONY L · 1985 to 2010
$1.8M
A Murine Model of Chronic Autoimmune Hepatitis and Liver FibrosisR01AI076357 · NIAID · DUKE UNIVERSITY · PI ZHONG, XIAOPING · 2008 to 2012
$1.5M
Regulation of B lymphocyte proliferation by antigenR56AI020038 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEFRANCO, ANTHONY L · 2013 to 2013
$363k
NIAID NIH HHS R01 AI020038NIAID NIH HHS R01 AI076357NIAID NIH HHS R01AI076357NIAID NIH HHS R01 AI079088NIAID NIH HHS R56 AI020038PHS HHS P01A1-078869PHS HHS R01A1-072058PHS HHS R01A1-20038
6 · The paper itself

Abstract

Signaling downstream of the B cell antigen receptor (BCR) is tightly regulated to enable cells to gauge the strength and duration of antigen-receptor interactions and to respond appropriately. We investigated whether metabolism of the second messenger diacylglycerol (DAG) by members of the family of DAG kinases (DGKs) played a role in modulating the magnitude of signaling by DAG downstream of the BCR. In the absence of DGKζ, the threshold for BCR signaling, measured as activation of the Ras-extracellular signal-regulated kinase (ERK) pathway, was markedly reduced in mature follicular B cells, which resulted in enhanced responses to antigen in vitro and in vivo. Inhibition of DAG signaling by DGKζ limited the number of antibody-secreting cells that were generated early in response to T cell-independent type 2 antigens, as well as to T cell-dependent antigens. Furthermore, the effect of loss of DGKζ closely resembled the effect of increasing the affinity of the BCR for antigen during the T cell-dependent antibody response. These results suggest that the magnitude of DAG signaling is important for translating the affinity of the BCR for antigen into the amount of antibody produced during the early stages of an immune response.

Indexed as

Adoptive TransferAnimalsAntibody Formationbcl-X ProteinBlotting, WesternB-LymphocytesCell ProliferationDiacylglycerol KinaseDiglyceridesExtracellular Signal-Regulated MAP KinasesFlow CytometryImmunoglobulin MLymphocyte ActivationMAP Kinase Signaling SystemMiceMice, Inbred C57BL1,2-diacylglycerolBcl2l1 protein, mousebcl-X ProteinDiacylglycerol Kinasediacylglycerol kinase zeta, mouseDiglyceridesExtracellular Signal-Regulated MAP Kinaseshen egg lysozymeImmunoglobulin MMuramidaseReceptors, Antigen, B-Cell

Identifiers

PMID24129701
PMCPMC4108475
OpenAlexW2134452781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.